Corporate Banner
Satellite Banner
Chromatography
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Onyx to Expand Capabilities

Published: Tuesday, August 07, 2012
Last Updated: Tuesday, August 07, 2012
Bookmark and Share
Reach alliance broadens specialist purification, separation services.

Onyx Scientific has announced a collaboration with a purification specialist that will see the company broaden its offering to the global pharmaceutical and biotech industry.

The contract manufacturing organization (CMO) has struck-up a strategic alliance with UK-based Reach Separations, which will allow it to deliver more specialist purification and separation services to bolster its early stage development services.

As part of the deal, Onyx Scientific will be now able to offer custom separation for companies in drug discovery and intermediate environments.

This includes chiral, reverse phase and normal phase chromatography using Supercritical Fluid Chromatography (SFC) and High Performance Liquid Chromatography (HPLC).

With MHRA and FDA licensed facilities in the UK and India, Onyx Scientific supports pharmaceutical and biotech companies from medicinal chemistry and preclinical through Phase I-III, scaling-up to large scale commercial API production.

Denise Bowser, commercial director at Onyx Scientific, said: “We were very impressed with the major equipment investment at Reach Separations and the team’s exceptional knowledge in understanding our clients’ challenges in small scale purification.

“Given this is an area that we have limited expertise and one that clients look to outsource, it made perfect sense for us to plug the gap and complement our existing services by working with Reach Separations.

“We expect this strategic partnership will play an important role in giving our clients quicker access to these types of services but with the added benefit of knowing it will be managed by us as part of the overall project,” added Denise.

Reach Separations is located in BioCity in Nottingham, which is one of Europe’s largest bioscience incubators that currently hosts over 70 companies and has a rich heritage in drug discovery.

The company’s technical group is led by purification specialist and Technical Director Phil Abbott. He has worked in the pharmaceutical industry for almost 20 years, including several years at AstraZeneca as a Separation Science Group Leader.

He said: “We are delighted to be working alongside Onyx Scientific given the company’s fine reputation in contract medicinal chemistry, scale-up and manufacturing for the world’s drug development industry.

“We have strong experience in the pharmaceutical outsourcing sector so understand the challenges and issues clients face. Our role will be to bring our expertise to the table and work as part of the Onyx team to ensure clients’ requirements are always met and timelines never exceeded.”

Working as a preferred partner of many of the world’s top pharma firms, Onyx Scientific’s UK labs in North East England deal with complex chemical services and deliver early stage programs involving custom synthesis, lead optimization, chemical process development, solid-state chemistry and GMP synthesis.

It is then able to scale-up, internally tech transfer and provide increased efficiency for clients from its commercial manufacturing sites in India.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Grant to Fund Million Peaks Project
The European Research Council (ERC) has awarded a prestigious Advanced Grant to Prof. Peter Schoenmakers, Prof. Albert Polman and Prof. Huib Bakker, all three of whom work at the University of Amsterdam (UvA).
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Why Bearcats Smell Like Buttered Popcorn
Researchers pinpoint chemical compound that gives rare animal its popcorn-like scent.
Human Gut Microbiome Evolution
Westerners have a less-diverse gut microbiome compared to hunter-gatherers, but how and why these microbe collections diverged has largely remained a mystery.
Potential Diagnostic for Dengue Fever
Scientists from Colorado State University have explored the use of small molecules in patient serum for diagnosis of dengue fever and potentially predicting progression to the severe disease.
Non-Destructive Sensing of Fish Freshness
Is there any reliable way to know whether frozen fish is fresh or not?
‘Smelling’ Prostate Cancer
A research team from the University of Liverpool and the University of the West of England (UWE Bristol) has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Portable Kit Can Recover Traces of Chemical Evidence
A chemist at the National Institute of Standards and Technology (NIST) has developed a portable version of his method for recovering trace chemicals such as environmental pollutants and forensic evidence including secret graves and arson fire debris.
Diagnosis of Two Rare Childhood Diseases Improved
For the first time, researchers have developed tests that could improve the diagnosis of two rare childhood diseases known as congenital disorders of glycosylation (CDGs) and metachromatic leukodystrophy, and that could even lead to new treatments for CDGs.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!